Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18068087 | 0.84 | NOS3 (0.33) | NOS3NOS1NOS2LMNAACHE | |
| SCHEMBL12895995 | 0.83 | NOS3 (0.46) | NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL12796016 | 0.80 | CA1 (0.33) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL12749938 | 0.79 | NOS3 (0.55) | NOS3NOS1NOS2 | |
| SCHEMBL2611021 | 0.78 | UHRF1 (0.50) | LMNAACHETRPA1CHRM1SLC6A2 | |
| SCHEMBL18068021 | 0.77 | GABRA1 (0.35) | LMNAACHEP2RX3P2RX2 | |
| SCHEMBL18068022 | 0.77 | GABRA1 (0.35) | LMNAACHEP2RX3P2RX2 | |
| SCHEMBL24802281 | 0.77 | PSMD14 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL12303999 | 0.77 | UHRF1 (0.56) | NOS3NOS1NOS2LMNAPOLB | |
| SCHEMBL22725593 | 0.77 | NOS3 (0.32) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024123966-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024028363-A1 | HETEROARYL CARBOXAMIDE AND RELATED GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024028364-A1 | ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024028365-A1 | SUBSTITUTED PYRIDONE GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | INSILICO MEDICINE IP LIMITED (HK) | 2023-12-05 | — | — | US | disclosed |
| WO-2023230026-A1 | PIPERIDINYL-METHYLPURINE BENZENES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022187518-A1 | SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20210147368-A1 | ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | disclosed |
| US-20200223808-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| US-9975896-B2 | Inhibitors of transcription factors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180030031-A1 | COMPOUNDS CONTAINING CARBON-CARBON LINKER AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2018-02-01 | — | — | US | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | NOS3 3453/4885NOS1 4527/4885NOS2 4450/4885 |
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | BRD4, BRPF3, EP300 | NOS3 3644/4885NOS1 3859/4885NOS2 3665/4885 |
| US-20200223808-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CYP7A1, VAPB, SLC10A1 | NOS3 2828/4885NOS1 1962/4885NOS2 3964/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | NOS3 4492/4885NOS1 4507/4885NOS2 4343/4885 |
| US-20210147368-A1 | ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CYP7A1, NAT1, NCOA1 | NOS3 2711/4885NOS1 1823/4885NOS2 3881/4885 |
| US-20180030031-A1 | COMPOUNDS CONTAINING CARBON-CARBON LINKER AS GPR120 AGONISTS | GPR180, GPR68, GPR88 | NOS3 844/4885NOS1 743/4885NOS2 677/4885 |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | QPCT, QPCTL, BCAT1 | NOS3 3898/4885NOS1 3424/4885NOS2 2708/4885 |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | NOS3 4121/4885NOS1 3843/4885NOS2 3301/4885 |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | NOS3 4121/4885NOS1 3843/4885NOS2 3301/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | NOS3 248/4885NOS1 335/4885NOS2 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.